73 results about "Bacterial polysaccharide" patented technology

The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to specific advantageous pnumococcal polysaccharide conjugates adjuvanted with 3D-MPL and substantially devoid aluminium-based adjuvant.

The invention relates to a bacterial polysaccharide-protein conjugate vaccine with immunogenicity, in particular to a conjugate vaccine which is formed by connecting a recombinant rotavirus protein with a bacterial polysaccharide by using a covalent bond, a nucleotide sequence for coding the recombinant rotavirus protein, a recombinant expression system, a protein expressed by the recombinant expression system, a preparation method of the conjugate vaccine and a pneumococcus polysaccharide-recombinant rotavirus protein conjugate vaccine. The bacterial polysaccharide is connected with a recombinant rotavirus surface protein through a covalent bond. The recombinant rotavirus protein is selected from a partial or complete amino acid sequence of a P-gene rotavirus protein and a partial or complete amino acid sequence of a G-gene rotavirus protein.

The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen from Streptococcus pneumoniae selected from the group consisting of PhtA, PhtD, PhtB, PhtE, SpsA, LytB, LytC, LytA, Sp125, Sp101, Sp128, Sp130 and Sp133, and optionally a Th1-inducing adjuvant.

Process for conjugation of bacterial saccharides including Streptococcus pneumoniae and Haemophilus influenzae saccharides by reductive amination are provided herein.

Process for the preparation of O-sulfated K4, K5 and K40 polysaccharides useful for the treatment of tumoral, HIV-1 and coagulation pathologies and in cosmetic preparations, wherein the K4, K5 or K40 polysaccharide in the form of sodium salt is suspended in an aprotic solvent and directly submitted to the reaction of O-sulfation with a pyridine-sulphur trioxide or trimetylamine-sulphur trioxide adduct or with chlorosulfonic acid.

The invention relates to nucleic acid sequences and related compositions for producing over-expression of the polysaccharide PNAG of Staphylococci. PNAG may be isolated and formulated into vaccines or used to generate antibodies. Binding agents of the nucleic acids are also described. The invention also relates to diagnostic and therapeutic methods using the compositions.

A preparing method of a recombinant fusion protein modified with bacterial polysaccharides and applications thereof are disclosed. The method includes co-expressing a recombinant fusion protein and neisseria meningitide O-oligosaccharyltransferase PglL in a bacterium with O-antigen ligase gene defect, and allowing polysaccharides of the bacterium or exogenous polysaccharides to be connected to the recombinant fusion protein through the neisseria meningitide O-oligosaccharyltransferase PglL to obtain the recombinant fusion protein modified with the bacterial polysaccharides. A specific antibody resisting bacterial polysaccharides can be prepared through immunizing mice with the prepared recombinant fusion protein modified with the bacterial polysaccharides. Through applying the recombinant fusion protein modified with the bacterial polysaccharides to preparation of bacterial polysaccharide protein conjugate vaccines, a plurality of problems of culturing of pathogenic bacteria can be avoided, homogeneity and a production efficiency of the vaccines can be increased and a vaccine preparing cost can be reduced.

A method comprises preventing or inhibiting bacterial adhesion and / or bacterial biofilm development by treating a substrate with a composition of a soluble group II capsular polysaccharide obtained from a bacterial strain.

The invention provides a nano selenium micromolecular microbial polysaccharide, which is prepared under ultrasonic condition by taking micromolecular Caragana rhizobia extracellular polysaccharide as a raw material through uniformly dispersing and co-acting with selenium dioxide and a reducing agent. The production method specifically comprises the steps of: preparing a micromolecular bacterial polysaccharide solution with a proper concentration, uniformly mixing micromolecular Caragana rhizobia polysaccharide with vitamin C, slowly dropwise adding selenium dioxide to the mixed system, carrying out ultrasonic dispersion and reaction, dialyzing and freeze-drying. The nano selenium micromolecular microbial polysaccharide product prepared by the preparing process has the selenium content up to 15.2-16.4mu g / mg, selenium average grain size about of 380 nm and polysaccharide yield more than70%. Mouse test shows that the nano selenium micromolecular polysaccharide has excellent anticancer activity, and can be applied to preparing anticancer medicaments and health products.

The invention discloses a removing method of endotoxin in the bacterial polysaccharide through large-hole resin in the biological technical domain, which comprises the following steps: fermenting bacteria through biological reactor; making rough sugar; extracting rough sugar through cooled phenol to remove protein; hyperfiltering through composite buffer of calcium ionic chelant-surface activator; removing endotoxin adsorbed by large-hole resin; obtaining bacterial polysaccharide with low endotoxin content.

The invention relates to novel, probiotic, anti-inflammatory strains of Bifidobacterium longum, their use for treatment of diseases, and for preparation of human or pet food or pharmaceutical compositions. The strains produce high amounts of exopolysaccharides with a high content of mannose- and glucose residues. Accordingly, the invention also relates to a bacterial polysaccharide composition obtained from the strains, their use for treatment of diseases, and pharmaceutical compositions comprising such polysaccharides.

The invention provides a multivalent immunogenic composition containing enterovirus antigens. The composition comprises inactivated EV71 antigens and / or inactivated CA16 antigens, and inactivated polio antigens. The composition can further comprise antigens selected from hepatitis A antigens, hepatitis B antigens, acellular pertussis antigens, tetanus toxoid, diphtheria toxoid, Haemophilus influenzae type b capsular polysaccharide, and meningococcal polysaccharide antigens, as well as physiologically acceptable carriers combined with bacterial polysaccharide antigens. The invention also provides a preparation method of the composition. The composition can prevent invasion of a plurality of pathogens simultaneously without interference among the antigens, and the immunogenicity is no less than that of individually activated antigens. With the composition, vaccination processes are significantly simplified, and the vaccination efficiency is improved with reduced costs.

The invention relates to a polysaccharide conjugate vaccine, which comprises a chemical conjugate consisting of a bacterial polysaccharide and a vector protein, wherein the vector protein is a bacterial slime invasion-associated protein, such as a bacillus coli heat-labile toxin B subunit, a campylobacter jejuni flagellum secretion protein A1, a campylobacter jejuni flagellum secretion protein A2, a pneumococcus surface protein and a pneumococcus surface adhesin. The invention further relates to a preparation method for the polysaccharide conjugate vaccine. According to the invention, the mucosa delivery of the polysaccharide conjugate vaccine can be realized on the premise of not adding any other extrinsic protein; and due to the adoption of an immune route, the vaccine is more efficient, convenient and safe to use.

Process for conjugation of bacterial saccharides including Streptococcus pneumoniae and Haemophilus influenzae saccharides by reductive amination are provided herein.

The instant invention provides improved culture, fermentation and purification conditions for preparing Neisseria meningitidis polysaccharides. The invention in particular relates to a novel fermentation medium, optimal feed solution addition strategies and an improved purification process devoid of any chromatographic methods for obtaining high yield of Neisseria meningitidis X polysaccharide.

The invention discloses a bacterial polysaccharide O-glycosylation modified recombinant cholera toxin B subunit fusion protein and an application thereof. The present invention provides a conjugate of polysaccharide and protein which is coupled by the bacterial polysaccharide and recombinant cholera toxin B subunit fusion protein. The bacterial polysaccharide is connected with the glycosylation sites of the recombinant cholera toxin B subunit fusion protein in the form of O-glucosidic bond. The experiment indicates that the preparation of the bacterial polysaccharide protein conjugate vaccine from O-glycosylation modified recombinant cholera toxin B subunit fusion protein can enhance the ability of inducing animals to generate anti-polysaccharide antibodies, avoid miscellaneous problems of pathogen culture, enhance the vaccine homogeneity and production efficiency, and reduce the vaccine preparation cost, therefore possessing wide application prospect.

The invention discloses a purifying method of bacterial polysaccharide through Sepharose 4FF gel in the biological technical domain, which comprises the following steps: predisposing bacterial polysaccharide; purifying; collecting component before Kd0.5; obtaining high-purity and low-endotoxin product.

This invention relates to modified pneumolysin polypeptides that retain the immunogenic nature of pneumolysin but have reduced or undetectable hemolytic activity compared to native pneumolysin. The invention also provides a method for generating novel pneumolysin variants with these desired characteristic properties. The invention also provides immunogenic compositions useful as pharmaceutical compositions including vaccines in which non-toxic, modified pneumolysin is used to stimulate protective immunity against Streptococcus pneumoniae. The vaccines may be compositions in which the modified pneumolysin is conjugated to bacterial polysaccharides or may be carried on an attenuated viral vector. In addition, the invention also provides a method of using the non-toxic, modified pneumolysin toxoid in order to stimulate antibodies against Streptococcus pneumoniae in a treated individual which are then isolated and transferred to a second individual, thereby conferring protection against Streptococcus pneumoniae in the second individual.

The invention discloses a bacterial polysaccharide protein conjugate vaccine using a hepatitis B surface antigen as carrier protein and a preparation method of the bacterial polysaccharide protein conjugate vaccine. According to the vaccine, protein is the hepatitis B surface antigen, and a bacterial polysaccharide is selected from any one or more of a haemophilus influenza type b polysaccharide, group A, group C, group Y and group W135 meningococcal polysaccharides, a salmonella typhi type Vi polysaccharide, a group B streptococcus type Ia polysaccharide and the like, pneumococcus serotype type 1, 2 and the like, and salmonella paratyphi type A or salmonella paratyphi type B. Animal experiments show that the antibody positive conversion rates of the bacterial polysaccharide and the hepatitis B surface antigen in the vaccine are both more than 85%, so that the vaccine is relatively high in antibody positive conversion rate; carrier protein plays a role in transforming the bacterial polysaccharide from a T-cell-independent antigen into a T-cell-dependent antigen, and also can be used for preventing diseases caused by hepatitis B virus; and by adopting the bacterial polysaccharide protein conjugate vaccine disclosed by the invention, the problem of performing immunization inoculation on infants and young children under 2 years old can be solved, the function of one injection with multiple immune effects also can be achieved, and the use crowd and coverage rate of the vaccine can be expanded.

The instant invention provides improved culture, fermentation and purification conditions for preparing Neisseria meningitidis polysaccharides. The invention in particular relates to a novel fermentation medium, optimal feed solution addition strategies and an improved purification process devoid of any chromatographic methods for obtaining high yield of Neisseria meningitidis X polysaccharide.

The present invention relates to an immunomodulator composition, and a pharmaceutical composition and applications thereof. The immunomodulator composition consists of a variety of bacterial polysaccharide extracts, wherein at least a bacterial polysaccharide extract derived from mycobacterium and a polysaccharide extract derived from pneumococcus are comprised. The immunomodulator composition can stimulate a body to produce a sustained immune function of a significant effect, particularly non-specific immune response ability as well as secondary generated specific immune response on the basis thereof. Compared with immunomodulators already available in the market, the immunomodulator composition of the invention can improve the overall anti-infection, anti-tumor and anti-allergic abilities for human or animals.

A method of collecting, sterilizing, standardizing, drying and mixing rumen fluid while retaining the activity of the contained bacterial polysaccharides is described. Nutritional compositions including the resulting product, probiotics, nutricines, vitamins, minerals, an amino acid, and a monosaccharide are depicted. The use of this resulting nutritional composition the first few days of young animals' lives result in decreased diarrhea morbidity, severity and mortality. It also helps supply nutrients for the support of natural immune response and function.

The invention discloses a bacterial polysaccharides and protein binding combined vaccine for human, wherein Group A and Group B epidemic cerebrospinal meningitis Neisser's coccus capsular polysaccharides and Type B haemophilus influenzae capsular polysaccharide are bonded on an effective protein carrier with covalent bonds by a chemical method to prepare a preventive combined vaccine bonding polysaccharides and protein for human. Three vaccinations are conducted on children with the age of three to eight months and each for one month, and one vaccination is conducted on children older than one year. More than 96.5 percent of vaccine inoculators can be immunized from the Group A and Group C epidemic cerebrospinal meningitis Neisser's coccus and 91.2 percent of the vaccine inoculators can obtain long-term immunity from the Type B haemophilus influenzae one month after immunization. The vaccine is applied to the prevention of the infection caused by the Group A and Group C epidemic cerebrospinal meningitis Neisser's coccus and the Type B haemophilus influenzae.

The invention relates to novel completely biodegradable waterproof paper. The waterproof paper especially is waterproof paper and various kinds of packing paper, on surface of which pens can write and characters or patterns can be printed. The waterproof paper contains paper and its surface coating a polysaccharide ester film. A preparation method of the waterproof paper is coating technologies such as an impregnation method, a spray method, a scraping method and the like. The polysaccharide ester used contains cellulose ester, starch ester and bacterial polysaccharide ester (such as dextran ester). A solvent of the prepared coating contains polar / nonpolar organic solvents such as chloroform, dichloromethane, acetone, toluene and the like. The waterproof paper is water-repellent and has good writing ability and printability. Meanwhile, the selected raw materials have excellent biodegradability such that complete biodegradation can be realized under a specific condition. Thus, the waterproof paper has an excellent function of environmental protection.

The invention belongs to the technical field of biology, and relates to a bacterial strain for high-producing bacterial polysaccharide and a method thereof for preparing polysaccharide by fermenting traditional Chinese medicinal waste. The bacterial strain is preserved in the China Center for Type Culture Collection (CCTCC); the preservation number is CCTCC M 2016273. A bacterial strain of intermediate ochrobactrum ZY03 is inoculated in a culture medium with a sucrose content of 10g / L; the yield of the polysaccharide can reach 6g / L at most; the conversion ratio can reach 67 percent at most.

The present invention relates to the field of combined vaccine compositions which are effective against all forms of meningococcal diseases as well as typhoid fever. The vaccine formulations comprising antigens from capsular polysaccharides of Neisseria meningitidis A, Neisseria meningitidis C, Neisseria meningitidis Y, Neisseria meningitidis W135, Neisseria meningitidis X, Salmonella typhi Vi capsular polysaccharide (ViPs) or capsular ViPs conjugated to a carrier protein tetanus toxoid (ViPs-TT). This invention is also related to improved methods, especially the use of an improved feed media and an improved method of downstream processing and industrial purification of capsular polysaccharides. The vaccine is free of any animal component or alcohol and is in absolute compliance with respect to the religious sentiments of various ethnic groups. The composition is highly effective and stable, yet cost-effective and affordable, especially for lower-middle income and low-income countries.

The invention relates to the field of biology, in particular to application of an aminopeptidase reducing function in precaution and / or prevention of thallus biofilm formation, promotion of biofilm degradation and PslG release, reduction of the thallus content in a biofilm and improvement of antibiotic sensibility of thalli and application of an aminopeptidase reducing function method in preparation of drugs for precaution and / or prevention of thallus biofilm formation, promotion of biofilm degradation and PslG release, reduction of the thallus content in a biofilm and improvement of antibiotic sensibility of thalli. By adopting the aminopeptidase reducing function, lots of thalli in the biofilm are dead due to nutrition deficiency, dead bacteria release Psl polysaccharide hydrolase, hydrolysis of exopolysaccharides in the biofilm is promoted, and finally biofilm disruption is caused. Therefore, by developing drugs for aminopeptidase, biofilm disruption is promoted, the drug resistanceof biofilm thalli is reduced, and finally the purpose of removing harmful bacterium biofilms with antibiotics is achieved.

The invention discloses a biological preparation method of typhoid glycoprotein and an application thereof. The invention discloses a method for preparing bacteria polysaccharide-modified protein, a substrate protein of neisseria meningitidis O-oligosaccharyltransferase PglL and the neisseria meningitidis O-oligosaccharyltransferase PgIL are co-expressed in a bacteria defective in O-antigen ligase genes, and the bacteria polysaccharide-modified protein is obtained. The biological preparation method has wide application prospect for increasing uniformity of vaccine, increasing the production efficiency of the vaccine, and reducing cost; and the vaccine can be used for preventing the diseases caused by typhoid pathogen.

The invention provides a culture method for improving yield and viscosity of bacterial polysaccharides. By using the characteristic that penbritin can be simultaneously used as a mutagenic agent and bacterial cell wall peptidoglycan to synthesize stress factors, the penbritin is added to subsequent subculture processes of bacterial isolates for producing different polysaccharides; the adding amount of the penbritin is gradually increased along with an increase of passage number, so as to improve thrill on bacterial cells; and a series of high-producing strains with different viscosities and improvement degrees can be screened in the continuous passage process, so as to adapt to different application requirements. Therefore, the production cost is reduced.